Elif KILIÇ KÖNTE, Gülesser Eylül ŞİMSEK, Kübra UÇAK, Zeynep TORUNOĞLU, Ece ASLAN, Nergis AKAY, Ümit GÜL, Esma ASLAN, Aybüke GÜNALP, Fatih HAŞLAK, Mehmet YILDIZ, Amra ADROVİC, Sezgin ŞAHİN, Kenan BARUT, Özgür KASAPÇOPUR
Trends in Pediatrics - 2026;7(2):129-136
Objective: The coexistence of psoriasis and juvenile-onset systemic lupus erythematosus (jSLE) is rare, and data on familial aggregation of psoriasis across pediatric rheumatic diseases are limited. This study evaluated the co-existence of psoriasis in jSLE, its familial clustering, and its association with the jSLE phenotype. Methods: In this single-center cross-sectional study, patients with jSLE, familial Mediterranean fever (FMF), and juvenile systemic sclerosis (jSSc) were systematically screened for personal and family histories of psoriasis. Recurrence risk ratios for psoriasis were calculated separately for patients and their relatives within each disease group. Among patients with jSLE, clinical manifestations, laboratory parameters, and disease activity (SLEDAI-2K) were compared between those with and without personal and/or familial psoriasis. Results: Of 189 patients with pediatric rheumatic diseases included, 94 (49.7%) had jSLE, 73 (38.6%) had FMF, and 22 (11.7%) had jSSc; 69.3% were female, with a higher frequency in jSLE patients (85.1%). Overall, 7,034 individuals (patients and relatives) were systematically screened for psoriasis. Psoriasis was identified in 4 patients (2.1%), all with jSLE (4.3%), and in 25 relatives (0.36%), yielding an overall prevalence of 0.41%. The combined prevalence of psoriasis in jSLE patients and their relatives (0.54%) was significantly higher than in FMF (0.35%) and jSSc (0%) families (p = 0.034). Recurrence risk ratios (lambda) for psoriasis in jSLE families were 10.13 for patients and 3.07, 1.16, and 0.67 for first -, second-, and third-degree relatives, respectively; corresponding lambda values in FMF families were 0, 1.88, 1.11, and 0.45. Among 94 patients with jSLE, 20 had a personal or family history of psoriasis. However, their clinical signs, laboratory results, and SLEDAI-2K scores showed no significant differences compared with those without a history of psoriasis (p > 0.05). Conclusion: A positive family history of psoriasis is more common in jSLE than in FMF or jSSc, supporting the hypothesis of a shared genetic background between psoriasis and jSLE, but it was not associated with more severe jSLE in this cohort. These findings underscore the importance of routinely assessing familial psoriasis in jSLE and related disorders and warrant confirmation in larger, prospective, population-based studies.
